Patents by Inventor Jacqueline Wyatt

Jacqueline Wyatt has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Antisense modulation of protein phosphatase 2 catalytic subunit beta expression
    Patent number: 6602713
    Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of Protein Phosphatase 2 catalytic subunit beta. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding Protein Phosphatase 2 catalytic subunit beta. Methods of using these compounds for modulation of Protein Phosphatase 2 catalytic subunit beta expression and for treatment of diseases associated with expression of Protein Phosphatase 2 catalytic subunit beta are provided.
    Type: Grant
    Filed: February 9, 2001
    Date of Patent: August 5, 2003
    Assignee: ISIS Pharmaceuticals, Inc.
    Inventor: Jacqueline Wyatt
  • Antisense modulation of MEKK4 expression
    Publication number: 20030144242
    Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of MEKK4. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding MEKK4. Methods of using these compounds for modulation of MEKK4 expression and for treatment of diseases associated with expression of MEKK4 are provided.
    Type: Application
    Filed: February 21, 2003
    Publication date: July 31, 2003
    Inventors: Donna T. Ward, William Gaarde, Brett P. Monia, Jacqueline Wyatt
  • Antisense modulation of BH3 interacting domain death agonist expression
    Publication number: 20030130222
    Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of BH3 Interacting domain Death agonist. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding BH3 Interacting domain Death agonist. Methods of using these compounds for modulation of BH3 Interacting domain Death agonist expression and for treatment of diseases associated with expression of BH3 Interacting domain Death agonist are provided.
    Type: Application
    Filed: November 13, 2002
    Publication date: July 10, 2003
    Inventors: Hong Zhang, Jacqueline Wyatt
  • Antisense modulation of CD40 ligand expression
    Patent number: 6586245
    Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of CD40 ligand. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding CD40 ligand. Methods of using these compounds for modulation of CD40 ligand expression and for treatment of diseases associated with expression of CD40 ligand are provided.
    Type: Grant
    Filed: July 18, 2001
    Date of Patent: July 1, 2003
    Assignee: ISIS Pharmaceuticals, Inc.
    Inventors: C. Frank Bennett, Brenda F. Baker, Jacqueline Wyatt, Scott E. Davis
  • Methods for identifying compounds that inhibit or reduce PTP1B expression
    Publication number: 20030108883
    Abstract: The present invention relates to methods for identifying compounds that inhibit PTP1B mRNA and protein expression in insulin resistant non-human mammals.
    Type: Application
    Filed: February 12, 2002
    Publication date: June 12, 2003
    Inventors: Cristina M. Rondinone, James M. Trevillyan, Bradley A. Zinker, Jeffrey F. Waring, Mike Jirousek, Madeline M. Butler, Lex M. Cowsert, Brett P. Monia, Jacqueline Wyatt
  • Antisense modulation of inhibitor-kappa B kinase-gamma expression
    Publication number: 20030105037
    Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of inhibitor-kappa B kinase-gamma. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding inhibitor-kappa B kinase-gamma. Methods of using these compounds for modulation of inhibitor-kappa B kinase-gamma expression and for treatment of diseases associated with expression of inhibitor-kappa B kinase-gamma are provided.
    Type: Application
    Filed: October 6, 2001
    Publication date: June 5, 2003
    Applicant: Isis Pharmaceuticals Inc.
    Inventors: Brett P. Monia, Jacqueline Wyatt
  • Antisense modulation of phospholipase A2 group V expression
    Publication number: 20030100524
    Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of phospholipase A2 group V. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding phospholipase A2 group V. Methods of using these compounds for modulation of phospholipase A2 group V expression and for treatment of diseases associated with expression of phospholipase A2 group V are provided.
    Type: Application
    Filed: November 1, 2001
    Publication date: May 29, 2003
    Applicant: Isis Pharmaceuticals Inc.
    Inventors: C. Frank Bennett, Jacqueline Wyatt
  • Antisense modulation of hormone-sensitive lipase expression
    Publication number: 20030096771
    Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of hormone-sensitive lipase. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding hormone-sensitive lipase. Methods of using these compounds for modulation of hormone-sensitive lipase expression and for treatment of diseases associated with expression of hormone-sensitive lipase are provided.
    Type: Application
    Filed: July 26, 2001
    Publication date: May 22, 2003
    Inventors: Madeline M. Butler, Andrew T. Watt, Susan M. Freier, Jacqueline Wyatt
  • Antisense modulation of fibroblast growth factor receptor 3 expression
    Publication number: 20030087854
    Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of fibroblast growth factor receptor 3. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding fibroblast growth factor receptor 3. Methods of using these compounds for modulation of fibroblast growth factor receptor 3 expression and for treatment of diseases associated with expression of fibroblast growth factor receptor 3 are provided.
    Type: Application
    Filed: September 10, 2001
    Publication date: May 8, 2003
    Applicant: Isis Pharmaceuticals Inc.
    Inventors: Brett P. Monia, Jacqueline Wyatt
  • Antisense modulation of CD40 ligand expression
    Publication number: 20030083278
    Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of CD40 ligand. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding CD40 ligand. Methods of using these compounds for modulation of CD40 ligand expression and for treatment of diseases associated with expression of CD40 ligand are provided.
    Type: Application
    Filed: July 18, 2001
    Publication date: May 1, 2003
    Applicant: Isis Pharmaceuticals Inc.
    Inventors: C. Frank Bennett, Brenda F. Baker, Jacqueline Wyatt, Scott E. Davis
  • Antisense modulation of PKA regulatory subunit RII beta expression
    Publication number: 20030083281
    Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of PKA regulatory subunit RII beta. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding PKA regulatory subunit RII beta. Methods of using these compounds for modulation of PKA regulatory subunit RII beta expression and for treatment of diseases associated with expression of PKA regulatory subunit RII beta are provided.
    Type: Application
    Filed: July 25, 2001
    Publication date: May 1, 2003
    Applicant: Isis Pharmaceuticals Inc.
    Inventors: Brett P. Monia, Jacqueline Wyatt
  • Antisense modulation of transforming growth factor beta receptor II expression
    Publication number: 20030064944
    Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of Transforming growth factor beta receptor II. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding Transforming growth factor beta receptor II. Methods of using these compounds for modulation of Transforming growth factor beta receptor II expression and for treatment of diseases associated with expression of Transforming growth factor beta receptor II are provided.
    Type: Application
    Filed: June 21, 2001
    Publication date: April 3, 2003
    Applicant: Isis Pharmaceuticals Inc.
    Inventors: Susan Murray, Jacqueline Wyatt
  • Antisense modulation of phospholipid scramblase I expression
    Publication number: 20030044979
    Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of Phospholipid scramblase I. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding Phospholipid scramblase I. Methods of using these compounds for modulation of Phospholipid scramblase I expression and for treatment of diseases associated with expression of Phospholipid scramblase I are provided.
    Type: Application
    Filed: April 5, 2001
    Publication date: March 6, 2003
    Applicant: Isis Pharmaceuticals Inc.
    Inventors: C. Frank Bennett, Jacqueline Wyatt
  • Antisense modulation of phospholipase A2, group llA (synovial) expression
    Publication number: 20030045487
    Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of Phospholipase A2, group IIA (synovial). The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding Phospholipase A2, group IIA (synovial). Methods of using these compounds for modulation of Phospholipase A2, group IIA (synovial) expression and for treatment of diseases associated with expression of Phospholipase A2, group IIA (synovial) are provided.
    Type: Application
    Filed: May 25, 2001
    Publication date: March 6, 2003
    Applicant: Isis Pharmaceuticals Inc.
    Inventors: C. Frank Bennett, Jacqueline Wyatt
  • Antisense modulation of syntaxin 4 interacting protein expression
    Patent number: 6503756
    Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of Syntaxin 4 interacting protein. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding Syntaxin 4 interacting protein. Methods of using these compounds for modulation of Syntaxin 4 interacting protein expression and for treatment of diseases associated with expression of Syntaxin 4 interacting protein are provided.
    Type: Grant
    Filed: September 22, 2000
    Date of Patent: January 7, 2003
    Assignee: Isis Pharmaceuticals, Inc.
    Inventors: Susan M. Freier, Jacqueline Wyatt
  • Antisense modulation of BH3 interacting domain death agonist expression
    Patent number: 6503754
    Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of BH3 Interacting domain Death agonist. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding BH3 Interacting domain Death agonist. Methods of using these compounds for modulation of BH3 Interacting domain Death agonist expression and for treatment of diseases associated with expression of BH3 Interacting domain Death agonist are provided.
    Type: Grant
    Filed: September 7, 2000
    Date of Patent: January 7, 2003
    Assignee: ISIS Pharmaceuticals, Inc.
    Inventors: Hong Zhang, Jacqueline Wyatt
  • Antisense modulation of MEKK3 expression
    Patent number: 6498035
    Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of MEKK3. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding MEKK3. Methods of using these compounds for modulation of MEKK3 expression and for treatment of diseases associated with expression of MEKK3 are provided.
    Type: Grant
    Filed: September 8, 2000
    Date of Patent: December 24, 2002
    Assignee: Isis Pharmaceuticals, Inc.
    Inventor: Jacqueline Wyatt
  • Antisense modulation of GU protein expression
    Patent number: 6492172
    Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of GU Protein. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding GU Protein. Methods of using these compounds for modulation of GU Protein expression and for treatment of diseases associated with expression of GU Protein are provided.
    Type: Grant
    Filed: April 27, 2001
    Date of Patent: December 10, 2002
    Assignee: ISIS Pharmaceuticals, Inc.
    Inventors: C. Frank Bennett, Harris Busch, Jacqueline Wyatt
  • Antisense modulation of SR-CYP expression
    Patent number: 6475797
    Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of SR-cyp. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding SR-cyp. Methods of using these compounds for modulation of SR-cyp expression and for treatment of diseases associated with expression of SR-cyp are provided.
    Type: Grant
    Filed: November 3, 2000
    Date of Patent: November 5, 2002
    Assignee: ISIS Pharmaceuticals, Inc.
    Inventor: Jacqueline Wyatt
  • Antisense modulation of protein phosphatase 2 catalytic subunit alpha expression
    Patent number: 6465250
    Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of Protein Phosphatase 2 catalytic subunit alpha. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding Protein Phosphatase 2 catalytic subunit alpha. Methods of using these compounds for modulation of Protein Phosphatase 2 catalytic subunit alpha expression and for treatment of diseases associated with expression of Protein Phosphatase 2 catalytic subunit alpha are provided.
    Type: Grant
    Filed: February 9, 2001
    Date of Patent: October 15, 2002
    Assignee: ISIS Pharmaceuticals, Inc.
    Inventor: Jacqueline Wyatt